Skip to navigationSkip to contentSkip to footerHelp using this website - Accessibility statement
  • Advertisement

    Opinion

    Unloved healthcare stocks can reinvent themselves

    Those betting on the demise of blue-chip healthcare stocks like CSL and ResMed might want to rethink based on a review of Microsoft and Apple’s histories.

    Jun Bei LiuContributor

    Subscribe to gift this article

    Gift 5 articles to anyone you choose each month when you subscribe.

    Subscribe now

    Already a subscriber?

    The healthcare sector has become one of the most discussed topics in the sharemarket due to a severe sell-off. Once a highly coveted sector and a cornerstone of many Australian investment managers’ portfolios, it’s now being shunned like a structurally challenged cyclical business.

    Since January, the sector has experienced a 14 per cent decline, while the broader market has been flat over the same period. This makes it the poorest performing sector, even underperforming listed property.

    Subscribe to gift this article

    Gift 5 articles to anyone you choose each month when you subscribe.

    Subscribe now

    Already a subscriber?

    Read More

    Latest In Equity markets

    Fetching latest articles

    Most Viewed In Markets